Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV ...

China’s Ascletis Pharma has announced positive topline results from a US Phase II, 24-week study for its subcutaneous (SC) depot formulations of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 ...

Treatment with SC vs IV tocilizumab led to higher long-term remission rates in GCA-associated aortitis, though imaging and glucocorticoid-sparing outcomes were similar.

About Subcutaneous Administration Subcutaneous administration is a method of delivering medications under the skin. As an alternative to intravenous infusion, subcutaneous administration potentially ...

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

If approved, a subcutaneous formulation of anifrolumab would allow patients the ability to self-administer the medication outside of a hospital or clinic setting. The Food and Drug Administration (FDA ...

AbbVie Inc. (NYSE: ABBV ) is one of the best undervalued stocks to invest in right now.